
Healthcare
|
Clinical AI
|
Series D+
|
Valuation:
~$5.3B

Zeitgeist tracks private signals to determine where the company is heading and what it means competitively.
The company's public product roadmap & what they're committed to building.
Dedicated models for hematology-oncology, gastroenterology, and surgery targeting GA by end of 2025.
Expansion beyond outpatient visits into inpatient documentation and Epic order queuing for meds, labs, and imaging.
Prior authorization and RCM workflows built with Availity and Highmark Health.
Point-of-care prompts sourced from NEJM, JAMA, and Wolters Kluwer UpToDate.
Proprietary engine pairing ASR with clinical LLMs, with Linked Evidence mapping every summary line back to source audio.
Microsoft-backed incumbent with the largest install base, but weaker reputation for rapid iteration and specialty depth.
Cheaper and more EHR-agnostic, aimed at smaller practices rather than enterprise health systems.
Europe-born competitor strong on Meditech shops and clinician UX, but thinner on US enterprise Epic deployments.
CEO and Founder (practicing cardiologist at UPMC, ex-UPMC Enterprises)
CSO and CTO (CMU faculty, author of Dive into Deep Learning)
Chief Clinical Officer (ex-Senior Advisor to the US Surgeon General)
CFO (ex-Instacart CFO, ex-Accel)
2019 | Seed round (Y Combinator, Dupe Ventures, Gentex)
2023 | Series B, $30M
2024 | Series C, $150M at $850M valuation (Lightspeed, Redpoint, IVP, Bessemer, Kaiser Permanente Ventures, CVS Health Ventures)
2025 | Series D, $250M at $2.75B valuation (Elad Gil, IVP, NVIDIA NVentures, CapitalG)
2025 | Series E, $300M at $5.3B valuation (Andreessen Horowitz lead, Khosla Ventures, WndrCo)
